Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05719428 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neural Network-based Treatment Decision Support Tool in Patients With Refractory Solid Organ Malignancies

Study acronym: DRUID
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 25, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 30, 2024 to Dec 31, 2025
    • Study completion date: Dec 31, 2024 to Jun 30, 2026
    v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Start date changed from estimate of Apr 1, 2023 to Aug 28, 2023
    • Primary completion date: Jan 31, 2024 to Jun 30, 2024
    • Study completion date: Mar 31, 2024 to Dec 31, 2024
    • Site details revised
    • Study title shortened, about 5 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
DRUID is a treatment decision support tool combining predictive models and public databases related to multi-gene markers, drug response screens, gene essentiality and clinical status of drugs to provide drug recommendations personalized based on an input genomic profile. We hypothesize that DRUID analysis of patients' somatic mutational profile from NGS diagnostic platform can be used as a treatment decision support tool in patients with refractory cancer without targetable mutations.
Trial Details
NCT Number NCT05719428
Lead Sponsor National University Hospital, Singapore
Collaborators: National University of Singapore
Conditions
(from sponsor)		 Solid Organ Malignancies
Enrollment 37 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov